Background: This phase Ib study evaluated volociximab, an anti-α5β1 integrin antibody, in combination with carboplatin (Eli Lilly and Co., Indianapolis, IN) and paclitaxel (Taxol) in advanced, untreated non-small-cell lung cancer (NSCLC). Patients and methods: Three cohorts were treated with volociximab (10, 20, or 30 mg/kg) for up to six 3-week cycles in combination with carboplatin-paclitaxel chemotherapy and continued as maintenance therapy for patients with stable disease (SD) or better. Dose-limiting toxic effects, adverse events (AEs), pharmacokinetics, and antivolociximab antibodies were assessed.
Patients and methods: Three cohorts were treated with volociximab (10, 20, or 30 mg/kg) for up to six 3-week cycles in combination with carboplatin-paclitaxel chemotherapy and continued as maintenance therapy for patients with stable disease (SD) or better. Dose-limiting toxic effects, adverse events (AEs), pharmacokinetics, and antivolociximab antibodies were assessed.
Results: A maximum tolerated dose was not reached up to the maximum planned dose of 30 mg/kg. In 29 patients who received volociximab, the most common grade ≥3 AEs were neutropenia (24%), hyponatremia (17%), and fatigue (10%). Three patients experienced volociximab-related serious AEs. No hemorrhages were observed. Of 33 patients enrolled, 8 (24%) achieved a partial response and 17 (52%) had SD. The median progression-free survival was 6.3 months (95% confidence interval 5.5-8.1). Levels of potential biomarkers of angiogenesis or metastasis were reduced following six cycles of treatment.
Conclusions: Volociximab combined with carboplatin and paclitaxel was generally well-tolerated and showed preliminary evidence of efficacy in advanced NSCLC. Key words: integrin, monoclonal antibody, NSCLC, volociximab introduction
The introduction more than a decade ago of so-called thirdgeneration combination therapies, such as carboplatinpaclitaxel, cisplatin-paclitaxel, cisplatin-gemcitabine, and cisplatin-vinorelbine, led to modest improvements in survival when combined with platinum compounds in untreated patients with advanced non-small-cell lung cancer (NSCLC), resulting in 1-year survival rates of 31%-44% in patients with good performance status [1] [2] [3] . Bevacizumab, approved for treatment of non-squamous cell NSCLC, inhibits the expression of vascular endothelial growth factor (VEGF), a major regulator of tumor angiogenesis. Bevacizumab resulted in further survival gains but is not indicated for patients with squamous cell carcinoma because of its association with serious hemorrhagic complications in these patients [4, 5] . Therefore, additional treatments are needed for advanced NSCLC, particularly for the squamous cell histology.
Angiogenesis is stimulated by many growth factors [6] ; antiangiogenic agents that can act independently of individual growth factor effects may have therapeutic promise. Although the role of VEGF as an angiogenic growth factor is welldocumented, integrins are increasingly recognized for their important roles in angiogenesis. Integrins are cell surface receptors that allow cellular adhesion to the extracellular matrix [7] . The interaction between the α5β1 integrin and its ligand, fibronectin, plays a pivotal role in angiogenesis and is a promising target for anti-angiogenic therapy [8] .
Volociximab is a high-affinity, chimeric monoclonal antibody directed against human α5β1 integrin that has demonstrated in vitro and in vivo anti-angiogenic activity. Volociximab potently inhibited α5β1 binding to fibronectin and promoted apoptosis in endothelial cells in vitro [9] . This effect was limited to proliferating endothelial cells and was independent of stimulation by multiple growth factors, including VEGF. Similar effects have been demonstrated in several animal models of angiogenesis [9] [10] [11] . In clinical trials, volociximab was well-tolerated and showed preliminary evidence of efficacy in metastatic melanoma [12] , renal cell carcinoma [13] , and pancreatic cancer [14, 15] .
Based on these observations, a phase Ib dose-escalation study was conducted to evaluate the safety and pharmacokinetics of volociximab in combination with carboplatin and paclitaxel as first-line treatment in patients with stage IIIB/IV NSCLC.
methods objectives
The primary study objective was to determine the maximum tolerated dose (MTD) of volociximab in combination with carboplatin and paclitaxel (Taxol, Bristol-Myers Squibb Company Princeton, NJ) in patients with stage IIIB/IV NSCLC. Secondary objectives were to examine the efficacy, safety, pharmacokinetics, and immunogenicity of the combination and to examine the correlation between detectable levels of biomarkers and volociximab dose, response, and toxicity.
study participants
Eligible patients were aged ≥18, with stage IIIB (with pleural effusion)/IV or recurrent NSCLC and measurable disease according to the Response Evaluation Criteria in Solid Tumors (RECIST) [16] , who received no prior chemotherapy, biological therapy, or immunotherapy for stage IIIB/IV disease. Adjuvant therapy was permitted ≥6 months before study enrollment. Further eligibility criteria were Eastern Cooperative Oncology Group (ECOG) performance status ≤1 and adequate hepatic, renal, and bone marrow function. Exclusion criteria included a history of thromboembolic events or bleeding disorders, central nervous system metastases, oxygen-dependent chronic obstructive pulmonary disease, known active infections requiring IV treatment, autoimmune disease, or clinically important or unstable medical conditions. No concomitant use of immunomodulatory agents other than low-dose inhaled, intranasal, or oral corticosteroids was permitted.
study design and drug administration
This phase Ib, open-label, dose-escalation study was conducted at two sites in the United States and France. The protocol was approved by the ethics committees at both institutions and conducted in accordance with the Declaration of Helsinki, and recommendations of the US Food and Drug Administration and the International Conference on Harmonisation. All patients provided written informed consent to participate in the study. The study is registered at www.clinicaltrials.gov (NCT00654758).
Three successive patient cohorts were treated with escalating doses of volociximab (10, 20 , and 30 mg/kg) in combination with carboplatin and paclitaxel. Maintenance of a serum concentration of >3 µg/ml is sufficient to saturate the α5β1 integrin receptor on peripheral blood monocytes (unpublished data). Since it is unlikely that serum concentrations Annals of Oncology original articles accurately reflect tumor drug concentrations, a higher serum level was targeted in order to avoid underdosing patients. Prior pharmacodynamic analyses demonstrated that the volociximab saturation of the integrin receptor was dose-dependent up to 15 mg/kg [17] . This dose results in a trough serum concentration of 150 μg/ml, which is expected to provide an adequate margin.
Volociximab dose was escalated if <2 dose-limiting toxic effects (DLTs) occurred in six patients. A DLT was defined as treatment-related grade 4 thrombocytopenia, grade ≥3 febrile neutropenia, grade 4 neutropenia >7 days, or any grade ≥3 non-hematological adverse event (AE) except for nausea, vomiting, or diarrhea that responded to medical management. If the MTD was not reached at the maximum planned dose (MPD) of 30 mg/ kg, this dosing cohort was to be expanded to six additional patients, for a total planned enrollment of up to 24 patients.
Patients were treated for six cycles of 3 weeks duration. Volociximab (10, 20, or 30 mg/kg) was administered IV at 4 ml/min. Patients in cohorts 1 and 2 (10 or 20 mg/kg) received volociximab on day 1 of each cycle, with an additional loading dose on day 8 of the first cycle. The use of a loading dose was based on pharmacokinetic data, suggesting that this addition allowed the required trough levels to be rapidly attained and maintained over time (unpublished data). Patients in cohorts 1 and 2 who missed a loading dose in cycle 1 for any reason other than a DLT were considered ineligible for DLT evaluation and were replaced. 
study assessments
Assessments were completed throughout treatment and up to 90 days following the last dose of study drug. Patients with progressive disease (PD) or who discontinued volociximab were encouraged to return for follow-up visits. Patients with SD or better who received maintenance volociximab continued to be evaluated for safety and response. Safety analyses were carried out for all patients who received ≥1 dose of volociximab. AEs were assessed throughout the study from enrollment until 30 days after the last dose of volociximab, using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v3.0 grading system. Serious infections and late-emerging neurological signs or symptoms were recorded 45, 60, and 90 days after the last dose.
Radiographic imaging and RECIST criteria [16] were used to evaluate tumor response as complete response (CR), partial response (PR), SD, or PD. Tumors were assessed upon screening and every 6 weeks thereafter during the treatment, maintenance, and follow-up periods.
Volociximab-specific anti-drug antibody (ADAb) measurements were completed using blood samples obtained on day 1 of cycles 1, 3, and 5, every 6 weeks during the maintenance phase, and at 30, 60, and 90 days following last dose of volociximab. Volociximab peak (C max ) and trough (C min ) concentrations were measured on pre-and postdose serum samples on four occasions during cycle 1 (days 1, 3-6, 8, and 15) and on every subsequent treatment day; between 3 and 7 days following drug discontinuation; and at 14, 30, 45, 60, and 90 days following the last dose.
Concentrations of 10 biomarkers [carcinoembryonic antigen, fibroblast growth factor basic, inter-cellular adhesion molecule 1, interleukin 6 (IL-6), IL-8, matrix metalloproteinase 9 (MMP-9), tissue inhibitor of metalloproteinase 1 (TIMP-1), tumor necrosis factor α, vascular cell adhesion molecule 1, and VEGF] were tested in blood samples collected at screening, day 1 predose for each dosing cycle, and treatment cessation.
Biomarkers were measured using a multiplex assay on the Luminex platform (Austin, TX). Monoclonal antibodies for VEGF receptor 2 (VEGFR2), CD34, and CD45 were used to analyze and enumerate circulating endothelial progenitor cells (CEPCs).
statistical analyses
Efficacy analyses were carried out on the intent-to-treat (ITT) population, defined as all patients enrolled in the study. The efficacy end points were the objective response rate (combined CR and PR), duration of response, and progression-free survival (PFS). For the PFS analysis, surviving patients who did not have disease progression were censored on the date of the last RECIST assessment on which they were progression free. Patients who withdrew before the first postbaseline assessment were censored on the date of enrollment. Safety analyses were carried out for all patients who received ≥1 dose of study medication. DLT analyses were carried out for patients who completed the first cycle of treatment and did not miss the loading dose, if applicable. Table S1 , available at Annals of Oncology online. Most patients (91%) had stage IV disease. The predominant histology was adenocarcinoma in 24 patients; four had large cell carcinoma and five had squamous cell carcinoma. Twenty-one percent of patients had never smoked, and 58% had a performance status of zero at screening.
Of the 33 enrolled patients, 29 (88%) received ≥1 dose of study drug and were included in the safety population. Four patients (two each in the 10-and 20-mg/kg cohorts) experienced AEs before receiving the first treatment dose that led to withdrawal from the study. Among the treated patients, the most common reason for treatment cessation was disease progression (20 patients), followed by AEs (eight patients). Four patients died during the study, one before receiving any treatment, and all due to disease progression. An additional patient died ∼7 months following study completion, also due to disease progression.
maximum tolerated dose
Eleven, 8, and 6 patients were enrolled in the 10-, 20-, and 30-mg/kg cohorts, respectively, during the dose escalation phase. Two patients each in the 10-and 20-mg/kg cohorts withdrew due to AEs before dosing and were discontinued from the study. An additional two patients in the 10-mg/kg cohort did not receive a loading dose in cycle 1 due to an SAE and were therefore considered not eligible for DLT evaluation.
No DLT occurred during the first cycle in the 10-mg/kg cohort. One patient in the 20-mg/kg cohort experienced a DLT of small intestinal obstruction during cycle 1, which was attributed to volociximab on the basis of temporal relationship and biological plausibility. No DLT occurred during the first cycle in the 30-mg/kg cohort. An MTD was not reached up to the MPD of 30 mg/kg. Following dose escalation, an additional original articles Annals of Oncology eight patients were enrolled in cohort 3 to obtain additional safety, pharmacokinetic, and pharmacodynamic data.
safety
Patients received a median of eight volociximab treatment cycles (range 1-30). The median treatment duration was 5 months (range 0-20). No patients had a permanent discontinuation of volociximab during an infusion. For both paclitaxel and carboplatin, patients received a median of six treatment cycles (range 1-6) for a median duration of 3.5 months (range 0-4.3). One patient in the 20-mg/kg cohort had one dose of paclitaxel temporarily interrupted due to equipment difficulty. One patient permanently discontinued treatment due to experiencing an AE of anaphylactic shock during the initial paclitaxel infusion. There were no carboplatin dose interruptions. Table 1 lists AEs observed on study. No apparent dose relationship with type or severity of AEs was observed. Volociximab-related AEs occurred in 27 of 29 patients (93%); 20 patients (69%) experienced AEs during cycle 1 and 25 (86%) during later cycles. Volociximab-related AEs reported in more than 25% of patients were asthenia (66%), arthralgia (55%), constipation (41%), anorexia (41%), myalgia (38%), diarrhea (28%), nausea (28%), vomiting (28%), and fatigue (28%). Seven patients experienced 12 grade 3/4 AEs that were attributed to volociximab. Six patients experienced 11 grade 3 AEs and one patient experienced 1 grade 4 AE (neutrophil count decreased).
Three patients experienced volociximab-related serious AEs. A patient receiving 10 mg/kg experienced grade 3 deep vein thrombosis during cycle 4 and a patient receiving 10 mg/kg experienced grade 3 arterial occlusive disease during cycle 2. Grade 2 proteinuria developed during cycle 1 in a patient receiving 30 mg/kg. Three patients discontinued treatment due to AEs deemed to be related to volociximab (grade 3 deep vein thrombosis, grade 3 asthenia, and grade 3 arterial occlusive disease), all occurring in patients receiving the 10-mg/kg dose.
efficacy
In the ITT population (n = 33), eight patients (24%) experienced a confirmed or unconfirmed tumor response ( Table 2 ). All eight responses were PRs: three in the 10-mg/kg cohort, two in the 20-mg/kg cohort, and three in the 30-mg/kg cohort. The median duration of response was 92 (range 43-295) days. Three patients (9%) achieved a confirmed objective response, corresponding to an objective response rate of 9% [95% confidence interval (CI) 2% to 24%]. All three confirmed objective responses were PRs: two in the 20-mg/kg cohort and one in the 30-mg/kg cohort. The duration of confirmed tumor response was 92 and 295 days for the two patients in the 20-mg/kg cohort and 134 days for the patient in the 30-mg/kg cohort.
Median PFS was 6.3 (95% CI 5.5-8.1) months for all patients in the ITT population and 6.6 (95% CI 5.5-8.1) months for patients in the safety population.
immunogenicity, pharmacokinetics, and pharmacodynamics
No volociximab-specific ADAbs were detected. Peak and trough serum volociximab concentrations following the first dose are shown in Table 3 . Peak and trough concentrations 
Grade 4 Neutropenia 2 (22) 0 1 (7) 3 (10) a Safety population. b Additional AEs >10% considered to be medically relevant by the authors include dysphonia, epistaxis, hypertension, and thrombocytopenia (5 patients each, 17%). AE, adverse event.
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increased following subsequent doses, with less than two-fold drug accumulation over the course of treatment of the three dose groups. The drug level approached a steady state in cycle 2 in cohorts 1 and 2 and during the third cycle in cohort 3, which did not receive a loading dose. Dose levels of cohorts 2 (20 mg/kg with a loading dose) and 3 (30 mg/kg without a loading dose) had trough levels consistently above 150 µg/ml, the target level considered sufficient to saturate the integrin receptor. Of 10 biomarkers assayed in serum samples, three showed significant decreases (P < 0.05) during the course of treatment: IL-6, IL-8, and TIMP-1 (supplementary Table S2 , available at Annals of Oncology online). Eleven of the 14 patients who had pre-and post-treatment samples available had a decreased percentage of VEGFR2-positive circulating endothelial cells (CECs) after six cycles of volociximab plus chemotherapy, compared with baseline ( paired t-test, P = 0.009; Figure 1) . Results of the CEC analysis were similar in all three patient cohorts, suggesting that there was no dose-response relationship.
discussion
Volociximab targets the α5β1 integrin, a cell surface receptor that plays a critical role in cellular adhesion to the extracellular matrix. Integrin angiogenic activity is independent of growth factor activation of angiogenesis, which suggests that volociximab may inhibit angiogenic pathways independent of VEGF and other growth factors [9] . In addition to its antiangiogenic effect, volociximab may also directly suppress proliferation and migration of tumor cells that express the α5β1 integrin [9] [10] [11] . Early-phase clinical trials in patients with advanced-stage solid tumors suggest that volociximab 10 mg/kg is well-tolerated and showed preliminary efficacy when combined with the standard chemotherapy regimens.
A variety of drugs are in development that target the integrin family of cell surface receptors. The most advanced is cilengitide, a synthetic peptide α5-integrin inhibitor that is currently in phase III development for newly diagnosed glioblastoma (NCT00689221). Several integrin inhibitors have [18] , and intetumumab (CNTO 95), an anti-α5 integrin monoclonal antibody [19] . Several additional integrin inhibitors are in phase I development. In the present study, volociximab was well-tolerated; the MTD was not reached up to an MPD of 30 mg/kg. Eight patients (24%) achieved a PR (confirmed or unconfirmed) to the combination of volociximab, carboplatin, and paclitaxel. Volociximab serum concentration reached steady state after cycle 1 treatment for patients in the 10-and 20-mg/kg cohorts, who received an additional dose on day 8, and after cycle 3 for patients in the 30-mg/kg cohort.
In this study, five patients (17%) experienced grade 1/2 hypertension, none of which was considered related to volociximab. Hypertension is common with anti-angiogenic therapy, and especially with VEGF inhibitors [20] . In two phase III randomized studies of NSCLC treatment with the VEGF inhibitor bevacizumab, grade 3/4 hypertension was increased in patients receiving bevacizumab (6%-9% versus 0.7%-2%) [5, 21] . The lack of significant hypertension observed in this study suggests that volociximab has a distinct mechanism of action compared with VEGF inhibitors.
Volociximab treatment was associated with a decrease from baseline in CEPC levels, which have been implicated in tumor vascularization [22] [23] [24] [25] . The decrease in CEPC levels is consistent with the proposed anti-angiogenic activity of volociximab. This decrease may not solely be due to volociximab, since patients also received chemotherapy; however, a similar reduction in CEPC levels was observed in a volociximab monotherapy study in ovarian cancer [26] . These data suggest that CEPC should be further explored as a pharmacodynamic marker in future trials.
Volociximab was also associated with decreases of IL-8 and TIMP-1. Pulmonary stroma may potentiate IL-8 production and related tumor angiogenesis in NSCLC [27] . Overexpression of MMPs and TIMPs in multiple tumor types has been associated with increased tumor progression and metastatic potential. TIMP-1 and MMP-9 levels correlate with response to combination therapy with erlotinib and celecoxib in patients with NSCLC [28] . Thus, substantial decreases of both IL-8 and TIMP-1 upon treatment may signal beneficial patient outcome. The limited size and lack of a control arm in the present study precludes an analysis of the relationship of such decreases with volociximab.
In conclusion, this phase I study suggests that volociximab at 20 and 30 mg/kg every 3 weeks in combination with carboplatin and paclitaxel is well-tolerated, shows preliminary evidence of efficacy in patients with advanced NSCLC, and warrants further phase II development. Decreased CEPC in most patients suggests the anti-angiogenic biological activity of volociximab. PD data are, therefore, consistent with a unique, dual anti-tumor and anti-angiogenic mechanism of action for volociximab. 
